Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.

Plain-language guide to PMID 42340790 (2026): meta-analysis of Semaglutide and Glucagon, chronic and systemic inflammation.

Key Facts

PMID: 42340790
Journal: La Clinica terapeutica
Year: 2026
Study type: Meta-Analysis
Authors: Elganyny MKE et al. (15 authors)
DOI: 10.7417/CT.2026.2083

What This Paper Covers, in Plain Language

What It Covers

This meta-analysis looks at Semaglutide and Glucagon in the context of chronic and systemic inflammation.

To assess the effects of semaglutide on body mass index (BMI), blood pressure, renal function (eGFR), and albuminuria in non-diabetic patients with obesity and CKD or hypertension.

Why It Was Studied

Given the high cardiometabolic risk in this group and limited therapeutic options, evaluating semaglutide's role is crucial.

Who the Included Studies Covered

A total of 580 studies were screened; 3 eligible studies (n=430 participants) were included.

How the Review Was Done

This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines.

Data were extracted from a randomized controlled trial, a real-world observational dialysis study, and a large post hoc trial analysis.

Fixed-effect meta-analysis models were applied to estimate pooled effects on BMI, systolic blood pressure (SBP), and renal outcomes.

What Was Measured

Given the high cardiometabolic risk in this group and limited therapeutic options, evaluating semaglutide's role is crucial.

PubMed files the paper under topics including Semaglutide, Glucagon-Like Peptides, Obesity, Hypertension, Renal Insufficiency, Chronic, Blood Pressure and Hypoglycemic Agents.

Author keywords: Semaglutide; Non-diabetic CKD; Obesity; GLP-1 receptor agonist; Blood pressure; GFR; Albuminuria; Meta-analysis.

What This Means in Plain Language

This is a meta-analysis of Semaglutide and Glucagon in people with chronic and systemic inflammation.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (La Clinica terapeutica), a journal based in Italy.

More context: the Semaglutide compound page and the Glucagon compound page, Chronic and systemic inflammation research.

Our Notes on the Compounds

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.